|IP||0.2-1 μL/mg of lysate|
**********Please Note: Optimal concentrations/dilutions should be determined by the end user.**********
PARP1 was immunoprecipitated using:
Lane A:0.5 mg Jurkat Whole Cell Lysate0.5 µL anti-PARP1 mouse monoclonal antibody and 15 μl of 50 % Protein G agarose.Primary antibody:
Anti-PARP1 mouse monoclonal antibody,at 1:500 dilutionSecondary antibody:
Dylight 800-labeled antibody to Mouse IgG (H+L), at 1:7500 dilutionDeveloped using the odssey technique.
Performed under reducing conditions.Predicted band size: 113 kDa
Observed band size: 113 kDa
Anti-PARP1 mouse monoclonal antibody at 1:500 dilution
Lane A: Jurkat Whole Cell LysateLysates/proteins at 30 μg per lane.
Goat Anti-Mouse IgG H&L (Dylight800) at 1/15000 dilution.Developed using the Odyssey technique.
Performed under reducing conditions.Predicted band size:113 kDa
Observed band size:113 kDa
Poly (ADP-ribose) polymerase 1(PRAP1), also known as NAD(+) ADP-ribosyltransferase 1(ADPRT), is a chromatin-associated enzyme which modifies various nuclear proteins by poly(ADP-ribosyl)ation. The ADP-D-ribosyl group of NAD+ is transferred to an acceptor carboxyl group on a histone or the enzyme itself, and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety, building up a polymer with an average chain length of 20-30 units. The poly(ADP-ribosyl)ation modification is critical for a wide range of processes, including DNA repair, regulation of chromosome structure, transcriptional regulation, mitosis and apoptosis. PARP1 is demonstrateed to mediate the poly(ADP-ribose) ation of APLF (aprataxin PNK-like factor) and CHFR (checkpoint protein with FHA and RING domains), two representative proteins involved in the DNA damage response and checkpoint regulation. Further, It has been suggested that DNA-dependent protein kinase (DNA-PK), another component of DNA repair, suppresses PARP activity, probably through direct binding and/or sequestration of DNA-ends which serve as an important stimulator for both enzymes. PARP1 inhibitors is thus proposed as a targeted cancer therapy for recombination deficient cancers, such as BRCA2 tumors.